An NCI-designated Comprehensive Cancer Center
Edwin Maneul CV photo

Edwin Manuel, Ph.D.

Assistant Professor, Department of Immuno-Oncology
Clinical Expertise
  • Immuno-Oncology
Research Focus
  • Development of therapeutic strategies to induce effective anti-tumor immune responses
  • Approaches to target immunosuppressive pathways to improve efficacy of cancer immunotherapy
  • Elucidating molecular mechanisms that drive transitions from benign disease to malignancy
Email: [email protected]
The overall objective of our research program will be to continue to generate novel approaches that overcome tumor escape to elicit potent anti-cancer immune responses, which can then be translated to the clinic for the treatment of aggressive cancers.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Salazar MA, ER Manuel, W Tsai, M D’Apuzzo, L Goldstein, BR Blazar, and DJ Diamond. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunol doi:10.1080/2162402X.2016.1160184. 2016.
  • J Chen, DJ Diamond, and ER Manuel. Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. Pancreat Disord Ther 6: 167. 2016.
  • M Ouyang, EE White, H Ren, Q Guo, I Zhang, H Gao, S Yanyan, X Chen, Y Weng, AD Fonseca, ER Manuel, L Zhang, SL Vonderfecht, D Alizadeh, J Berlin, and B Badie. Metronomic doses of temozolomide enhance the efficacy of carbon nanotube CpG immunotherapy in an invasive glioma model. PLOS ONE. 11:e0148139. 2016.
  • ER Manuel, J Chen, M D’Apuzzo, MG Lampa, CB Thompson, TI Kaltcheva, T Ludwig, V Chung, and DJ Diamond. Salmonella-based therapy targeting indoleamine 2,3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan completely regresses aggressive pancreatic tumors. Cancer Immun Res 3(9): 1096-107. 2015.
  • X Xu, WA Hegazy, L Guo, X Gao, AN Courtney, S Kurbanov, D Liu, G Tian, ER Manuel, DJ Diamond, M Hensel, and LS Metelitsa. Effective cancer vaccine platform based on attenuated Salmonella and a type III secretion system. Cancer Res 74, 6260-6270. 2014.
  • ER Manuel, BR Blazar, and DJ Diamond. Tumor growth control with IDO-silencing Salmonella-Reply. Cancer Res 14:4592-3. 2013.
  • ER Manuel and DJ Diamond.  A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils. Author’s View. OncoImmunology 3:e23322-1,2. 2013.
  • CA Blache, *ER Manuel, TI Kaltcheva, AN Wong, JDI Ellenhorn, BR Blazar, and DJ Diamond. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.  Cancer Res 24:6447-56. 2012. (*co-first author)
  • ER Manuel, CA Blache, JDI Ellenhorn, and DJ Diamond. Survivin the battle against immunosuppression. Author’s View. OncoImmunology 2: 240-1. 2012.
  • Fan H, IY Zhang, X Chen, L Zhang, H Wang, AC Carvalho da Fonseca, ER Manuel, DJ Diamond, AA Raubitschek, and B Badie. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res 20:5628-38. 2012.
  • ER Manuel, CA Blache, R Paquette, TI Kaltcheva, H Ishizaki, JD Ellenhorn, M Hensel, L Metelitsa, and DJ Diamond. Enhancement of cancer vaccine therapy by systemic delivery of a tumor targeting Salmonella-based Stat3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 71:4183-91. 2011.
  • Ishizaki H, *ER Manuel, GY Song, T Srivastava, S Sun, DJ Diamond, and JD Ellenhorn. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immun 60:99-109. 2011. (*co-first author)
  • Zhao D, D Alizadeh, L Zhang, W Liu, O Farrukh, ER Manuel, DJ Diamond, and B Badie. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res 17:771-82. 2011.
  • Ishizaki H, GY Song, T Srivastava, K D Carroll, V Shahabi, ER Manuel, DJ Diamond, and JD Ellenhorn. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 33:609-17. 2010.
  • ER Manuel, WW Yeh, H Balachandran, RH Clarke, MA Lifton, and NL Letvin. Vaccination reduces simian-HIV sequence reversion through enhanced viral control. J Virol 84:12782-9. 2010.
  • ER Manuel, Z Wang, Z Li, . La Rosa, W Zhou, and D J Diamond. Intergenic region 3 of MVA is a functional site for insert gene expression and allows for potent Ag-specific immune responses. Virology 403:155-62. 2010.
  • ER Manuel, WW Yeh, MS Seaman, K Furr, MA Lifton, SL Hulot, P Autissier, and NL Letvin. Dominant CD8+ T lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus. J Virol 83:10028-35. 2009.
  • J Li, T Srivastava, R Rawal, ER Manuel, D Isbell, W Tsark, C La Rosa, Z Wang, Z Li, PA Barry, KD Hagen, J Longmate, and DJ Diamond. Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology 387:16-28. 2009.
  • SL Hulot, M S Seaman, P Sen, PA Autissier, ER Manuel, and NL Letvin. Diverse cross-reactive potential and V{beta} gene usage of an epitope specific CTL population in monkeys immunized with diverse HIV-1 Env immunogens. J Virol 83:9803-12. 2009.
  • P Sen, WA Charini, RA Subbramanian, ER Manuel, MJ Kuroda, PA Autissier, and NL Letvin. Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge. J Virol 82:805-16. 2008.
  • ER Manuel, WA Charini, P Sen, FW Peyerl, MJ Kuroda, JE Schmitz, P Autissier, DA Sheeter, BE Torbett, and NL Letvin. Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses. J Virol 80:12032-40. 2006.
  • FW Peyerl, DH Barouch, HS Bazick, ER Manuel, and NL Letvin. Use of molecular beacons for rapid, real-time, quantitative monitoring of cytotoxic T-lymphocyte epitope mutations in simian immunodeficiency virus. J Clin Microbiol 43:4773-9. 2005.
  • S Duensing, A Duensing, DC Lee, KM Edwards, SO Piboonniyom, ER Manuel, L Skaltsounis, L Meijer, and K Munger. Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23:8206-15. 2004.
  • J Hasskarl, S Duensing, ER Manuel, and K Munger. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene 23:1930-8. 2004.

View all publications

In The News
An Expert's Voice
Student intern Ben Nittayo | City of Hope

Students Today, Scientists Tomorrow: Interns Shine in the City of Hope Spotlight